These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 7086446)

  • 1. CSF and plasma GABA levels in Parkinson's disease.
    Abbott RJ; Pye IF; Nahorski SR
    J Neurol Neurosurg Psychiatry; 1982 Mar; 45(3):253-6. PubMed ID: 7086446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low CSF gamma-aminobutyric acid levels in Parkinson's Disease. Effect of levodopa and carbidopa.
    Manyam BV
    Arch Neurol; 1982 Jul; 39(7):391-2. PubMed ID: 7103767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF GABA levels in Parkinson's disease.
    de Jong PJ; Lakke JP; Teelken AW
    Adv Neurol; 1984; 40():427-30. PubMed ID: 6695622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Parkinson's disease with sodium valproate: clinical, pharmacological, and biochemical observations.
    Nutt J; Williams A; Plotkin C; Eng N; Ziegler M; Calne DB
    Can J Neurol Sci; 1979 Aug; 6(3):337-43. PubMed ID: 385131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich's ataxia, Parkinson's disease, and Huntington's chorea.
    Bonnet AM; Tell G; Schechter PJ; Grove J; Saint-Hilaire MH; De Smet Y; Agid Y
    Mov Disord; 1987; 2(2):117-23. PubMed ID: 2973560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low CSF GABA in Parkinsonian patients who respond poorly to therapy or suffer from the "on-off" phenomenon.
    Teychenné PF; Ziegler MG; Lake CR; Enna SJ
    Ann Neurol; 1982 Jan; 11(1):76-9. PubMed ID: 6120678
    [No Abstract]   [Full Text] [Related]  

  • 7. Gamma-aminobutyric acid (GABA) in cerebrospinal fluid.
    Kuroda H
    Acta Med Okayama; 1983 Jun; 37(3):167-77. PubMed ID: 6224397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease.
    Jiménez-Jiménez FJ; Molina JA; Vargas C; Gómez P; Navarro JA; Benito-León J; Ortí-Pareja M; Gasalla T; Cisneros E; Arenas J
    J Neurol Sci; 1996 Sep; 141(1-2):39-44. PubMed ID: 8880690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid GABA levels in various neurological and psychiatric diseases.
    Kuroda H; Ogawa N; Yamawaki Y; Nukina I; Ofuji T; Yamamoto M; Otsuki S
    J Neurol Neurosurg Psychiatry; 1982 Mar; 45(3):257-60. PubMed ID: 7086447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of gamma-aminobutyric acid in cerebrospinal fluid in various neurologic disorders.
    Manyam NV; Katz L; Hare TA; Gerber JC; Grossman MH
    Arch Neurol; 1980 Jun; 37(6):352-5. PubMed ID: 6446278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further characterization of in vitro conditions appropriate for GABA determination in human CSF: impact of acid deproteinization and freeze/thaw.
    Ferraro TN; Manyam BV; Hare TA
    J Neurochem; 1983 Oct; 41(4):1057-64. PubMed ID: 6225837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid gamma-aminobutyric acid in neurologic disease.
    Achar VS; Welch KM; Chabi E; Bartosh K; Meyer JS
    Neurology; 1976 Aug; 26(8):777-80. PubMed ID: 133299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Free and conjugated GABA in human cerebrospinal fluid: effect of degenerative neurologic diseases and isoniazid.
    Manyam BV; Tremblay RD
    Brain Res; 1984 Jul; 307(1-2):217-23. PubMed ID: 6235893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of freezing on gamma-aminobutyric acid levels in human cerebrospinal fluid.
    Abbott RJ; Keidan J; Pye IF; Nahorski SR
    J Neurochem; 1981 Oct; 37(4):1042-4. PubMed ID: 7320717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease.
    Molina JA; Jiménez-Jiménez FJ; Gomez P; Vargas C; Navarro JA; Ortí-Pareja M; Gasalla T; Benito-León J; Bermejo F; Arenas J
    J Neurol Sci; 1997 Sep; 150(2):123-7. PubMed ID: 9268238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamate and GABA levels in CSF from patients affected by dementia and olivo-ponto-cerebellar atrophy.
    Tosca P; Canevari L; Di Paolo E; Ferrari R; Verzé S; Zerbi F; Dagani F
    Acta Neurol Scand; 1992 Jun; 85(6):430-5. PubMed ID: 1353649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid gamma-aminobutyric acid variations in neurological disorders.
    Enna SJ; Stern LZ; Wastek GJ; Yamamura HI
    Arch Neurol; 1977 Nov; 34(11):683-5. PubMed ID: 143928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid choline levels are decreased in Parkinson's disease.
    Manyam BV; Giacobini E; Colliver JA
    Ann Neurol; 1990 Jun; 27(6):683-5. PubMed ID: 2360805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of the gamma-aminobutyric acid (GABA) derivative, baclofen, to stimulate growth hormone secretion in Parkinson's disease.
    Volpi R; Scaglioni A; Marcato A; Caffarra P; Rossi G; Caffarri G; Delsignore R; Chiodera P; Coiro V
    J Neural Transm Park Dis Dement Sect; 1991; 3(4):259-64. PubMed ID: 1772578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss.
    Kish SJ; Rajput A; Gilbert J; Rozdilsky B; Chang LJ; Shannak K; Hornykiewicz O
    Ann Neurol; 1986 Jul; 20(1):26-31. PubMed ID: 2874765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.